Corgi NVO 2x Daily 

NVOC seeks to deliver 200% of the daily performance of Novo Nordisk A/S (NYSE: NVO) through derivatives such as swap agreements and exchange-traded equity futures to create leveraged exposure. Novo Nordisk A/S is a healthcare company that discovers, develops, manufactures, and markets pharmaceutical products, focusing primarily on diabetes care, obesity treatments, hemophilia management, and growth hormone therapies. The portfolio is rebalanced at the end of each trading day to maintain its targeted leverage level, meaning returns over periods longer than a single day can differ significantly from two times the cumulative return of NVO due to compounding effects. Collateral supporting these derivative positions may be invested in money market instruments, repurchase agreements, or short-term US government securities.